Price
$259.33+63.24%1Y
1M+3.43%1Y+63.24%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above average8/10
Value45
Quality86
Momentum54
Growth52
P/E (TTM)27.6
Market Cap$549.78B
1Y Return+63.24%
5Y Return+68.70%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $11.82B (-3.68%)
●Other Immunology grew +3700.00% YoY●Stelara -77.57% YoY
SegmentLatestQoQYoY
- DARZALEX$2.21B+5.75%+20.72%
- Tremfya$1.04B+5.36%+73.96%
- INVEGASUSTENNAXEPLIONTRINZATREVICTA$758.0M+14.16%+21.28%
- Xarelto$642.0M+1.10%-6.96%
- GENERAL$569.0M+2.52%+4.60%
- TRAUMA$532.0M+3.91%+5.98%
- ADVANCED$477.0M0.00%+4.38%
- CONTACTLENSESOTHER$468.0M+2.63%+3.54%
- CARVYKTI$433.0M+9.34%+36.16%
- OPSUMITOPSYNVI$433.0M+5.87%+19.28%
- SPRAVATO$406.0M+0.25%+47.10%
- SPINEOTHER$387.0M-4.68%-0.26%
- UPTRAVI$385.0M-1.79%+5.48%
- ERLEADA$342.0M-9.52%+17.12%
- PREZISTAPREZCOBIXREZOLSTASYMTUZA$334.0M+6.03%+9.51%
- HIPS$277.0M+5.73%+5.32%
- CAPLYTA$270.0M+12.50%-
- Remicade$269.0M-17.48%-14.33%
- Simponi Simponi Aria$269.0M-12.94%-7.88%
- KNEES$239.0M+10.65%+3.46%
- Stelara$220.0M-78.47%-77.57%
- RYBREVANTLAZCLUZE$175.0M+28.68%+54.87%
- IMBRUVICA$143.0M-32.23%-39.15%
- Tecvayli$127.0M+10.43%+20.95%
- SURGICAL$111.0M-4.31%-2.63%
- TALVEY$101.0M+18.82%+48.53%
- Other Oncology$85.0M+51.79%+57.41%
- OTHERNEUROSCIENCE$38.0M-17.39%+35.71%
- Other Immunology$38.0M+216.67%+3700.00%
- CONCERTAMethylphenidate$22.0M+57.14%-42.11%
- Other$12.0M-7.69%-20.00%
- EDURANTrilpivirine$7.0M0.00%-12.50%
- Other Infectious Diseases$1.0M-75.00%-50.00%
- Baby Care---
- Beauty---
- COVID19---
- INVOKANAINVOKAMET---
- OPSUMIT---
- OTC---
- Oral Care---
- RISPERDALCONSTA---
- Womens Health---
- Wound Careand Other---
- ZYTIGA---